急性冠状动脉综合征患者应用依折麦布联合阿托伐他汀治疗的临床研究

Clinical research of ezetimibe combining atorvastatin for the treatment of patients with acute cute coronary syndrome

目的:观察依折麦布联合阿托伐他汀对急性冠状动脉综合征(ACS)患者血脂及心脏事件的影响,并对其安全性评价。方法:回顾性分析北京安贞医院2010年1月至2010年12月间,住院的ACS患者236例,其中应用依折麦布(10 mg/d)联合阿托伐他汀(10 mg/d)治疗的患者81例(A组),应用阿托伐他汀(20 mg/d)治疗的患者155例(B组),治疗8 w后,比较两组患者治疗前后hs-CRP、LDL-C、TC、TG及HDL-C的变化,心脏事件以及不良反应发生率。结果:两组患者基线资料、治疗期间腹胀等不良反应及病死率差异无统计学意义(P>0.05),治疗8w后,A组hs-CRP、LDL-C、TC值、再发心绞痛及再发心肌梗死比例显著低于B组,差异有统计学意义(P<0.05)。结论:对ACS患者联合应用阿托伐他汀与依折麦布显著降低hs-CRP、LDL-C、TC水平及心脏事件发生率,且不增加不良反应,安全有效。

Objective：To observe the effects of ezetimibe combining atorvastatin on levels of blood lipid and major adverse cardiac events in patients with acute coronary syndrome（ACS）.And do safety evaluation.Methods： Retrospective analysis of clinical data of 236 hospitalized patients with ACS in Anzhen Hospital from January 2010 to December 2010,Of these cases,81 received ezetimibe 10mg/d and atorvastatin 10mg/d treatment（group A）,155 only received atorvastatin 20 mg/d treatment（group B）.After 8 w treatment,hs-CRP,Low density lipoprotein cholesterol（LDL-C）,total cholesterol（TC）,triglyceride（TG）,high-density lipoprotein cholesterol（hdl-C）,major adverse cardiac events and adverse reaction rate in these two groups were compared with before and after treatment and each other to observe the therapeutic effects.Results： The baseline information of the patients,adverse reactions rate such as abdominal distension etc.and mortality were similar between the two groups（P0.05）.After 8 w treatment,compared with pro-treatment,in group A the levels of hs-CRP,LDL-C,TC and the incidence of refractory angina,reinfarction are much lower than those in group B with statistical significance（P0.05）.Conclusion： In ACS patients ezetimibe combining atorvastatin therapy could obviously lower the levels of hs-CRP,LDL-C,TC,the incidence of major adverse cardiac events.And did not increase the incidence of adverse reactions.It was safe and effective.